Non-Coding RNAs as Biomarkers and Therapeutic Targets for Diabetic Kidney Disease

• Main Authors: Yue-Yu Gu (Author), Fu-Hua Lu (Author), Xiao-Ru Huang (Author), Lei Zhang (Author), Wei Mao (Author), Xue-Qing Yu (Author), Xu-Sheng Liu (Author), Hui-Yao Lan (Author)
• Format: Book
• Published: Frontiers Media S.A., 2021-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 1663-9812; 10.3389/fphar.2020.583528
• Keywords: diabetic kidney disease; micro RNAs; long non-coding RNAs; TGF-β; fibrosis; inflammation; Therapeutics. Pharmacology; RM1-950
• Source: Frontiers in Pharmacology, Vol 11 (2021)

Diabetic kidney disease (DKD) is the most common diabetic complication and is a leading cause of end-stage kidney disease. Increasing evidence shows that DKD is regulated not only by many classical signaling pathways but also by epigenetic mechanisms involving chromatin histone modifications, DNA methylation, and non-coding RNA (ncRNAs). In this review, we focus on our current understanding of the role and mechanisms of ncRNAs, including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) in the pathogenesis of DKD. Of them, the regulatory role of TGF-β/Smad3-dependent miRNAs and lncRNAs in DKD is highlighted. Importantly, miRNAs and lncRNAs as biomarkers and therapeutic targets for DKD are also described, and the perspective of ncRNAs as a novel therapeutic approach for combating diabetic nephropathy is also discussed.